Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer (NSCLC) using a Simple Blood Test – Yahoo Finance

Creatv Microtech, a privately-held biotechnology company has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy (CRT) and consolidated immunotherapy. Clinical data presented at the ASCO 2020 virtual annual meeting shows the ability to predict which NSCLC patients will benefit from anti-PD-L1/PD-1 immunotherapies. "We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT," said Dr. Cha-Mei Tang, CEO of Creatv. "Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies." Currently, no other blood test can predict immunotherapy treatment response for lung cancer.” data-reactid=”20″>Creatv Microtech, a privately-held biotechnology company has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy (CRT) and consolidated immunotherapy. Clinical data presented at the ASCO 2020 virtual annual meeting shows the ability to predict which NSCLC patients will benefit from anti-PD-L1/PD-1 immunotherapies. “We are delighted to present a method to stratify patients responding to immunotherapy by a single tube of blood collected after completion of CRT,” said Dr. Cha-Mei Tang, CEO of Creatv. “Early identification of patients that do not respond to immunotherapy will reduce unnecessary patient suffering from ineffective and costly treatment, allowing patients to proceed to alternative therapies.” Currently, no other blood test can predict immunotherapy treatment response for lung cancer.

here.” data-reactid=”23″>The poster is available here.

https://creatvBIO.com” data-reactid=”28″>Website: https://creatvBIO.com

https://www.businesswire.com/news/home/20200612005047/en/” data-reactid=”29″>View source version on businesswire.com: https://www.businesswire.com/news/home/20200612005047/en/

ron@creatvmicrotech.com

dan@creatvmicrotech.com